
Validea's guru fundamental report assigns Amgen (AMGN), a large-cap growth stock in the Biotechnology & Drugs sector, an 81% rating from Pim van Vliet's Multi-Factor Investor model. This strategy seeks low volatility stocks exhibiting strong momentum and high net payout yields. The 81% score signifies "some interest" in AMGN based on its fundamental and valuation profile, reflecting the model's premise that low-volatility assets can yield strong returns.
Amgen (AMGN) receives a mixed evaluation from Validea's Multi-Factor Investor model, based on Pim van Vliet's strategy targeting low-volatility stocks with strong momentum and high net payout yields. The stock achieves an 81% rating, signifying "some interest" from the model, and successfully passes criteria for Market Cap and Standard Deviation, aligning with the strategy's core preference for conservative, low-risk equities. However, the analysis reveals underlying weaknesses, as AMGN scores only "NEUTRAL" on two other key pillars of the strategy: "Twelve Minus One Momentum" and "Net Payout Yield." Most critically, despite the positive 81% headline score, the detailed summary table indicates a "FAIL" for the stock's "FINAL RANK." This contradiction suggests that while AMGN exhibits desirable low-volatility characteristics, its performance on momentum and shareholder return metrics is not strong enough to meet the strategy's comprehensive requirements for a definitive positive signal.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment